Biogen to present updates on MS therapies at ECTRIMS
At the Congress of the European Committee for Treatment and Research in MS, or ECTRIMS, Biogen will present data in more than 70 oral and poster presentations on its portfolio of multiple sclerosis, or MS, products and innovative research efforts aimed at transforming the care of people living with the disease. Key updates at ECTRIMS include clinical data and real-world evidence that further support the long-term efficacy and well-characterized safety of Biogen's MS therapies, including data supporting the use of Tecfidera and Tysabri early within the disease course. Additional data highlight the potential utility of serum neurofilament light, or sNfL, as a biomarker of MS disease activity. Biogen will also share updates on its efforts to improve monitoring of cognition and other key MS outcomes through MS PATHS.